Acceleron to Host Research and Development Day on October 23
15 Octubre 2015 - 6:30AM
Business Wire
– Presentations Will Highlight Luspatercept
Phase 3 Trial Designs, ACE-083 Phase 1 Trial Results, and the First
Clinical Candidate from Acceleron’s New IntelliTrapTM Discovery
Platform –
– Presentations to be given by members of
Acceleron and Celgene management and external clinical experts
–
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutic candidates that regulate
cellular growth and repair, today announced that it will host its
Research and Development (R&D) Day for investors and analysts
on Friday, October 23, 2015. The event will take place from
9:00 a.m. to 12:00 p.m. EDT in New York City.
At R&D Day, Acceleron and its collaboration partner,
Celgene, will review the Phase 3 clinical development plan for
luspatercept in myelodysplastic syndromes (MDS) and
beta-thalassemia.
Acceleron will present preliminary Phase 1 results from ACE-083,
its locally-acting muscle therapeutic, and provide updates on
sotatercept and dalantercept in chronic kidney disease and cancer,
respectively. In addition, the company will introduce its new drug
discovery platform, IntelliTrapTM and ACE-2494, a systemic muscle
therapeutic and the first clinical candidate to emerge from this
platform.
Along with the Acceleron team, presentations will be given by
outside experts to discuss the luspatercept clinical program and
disease treatments, including MDS, beta-thalassemia and muscular
dystrophies.
Guest speakers:
- Jay Backstrom, M.D., M.P.H., Senior
Vice President, Hematology & Oncology R&D, Global Head
Regulatory Affairs, Celgene
- Uwe Platzbecker, M.D., Professor of
Hematology and Head of the MDS Program, University Hospital
Dresden, Germany
- Domenica Cappellini, M.D., Director of
the Department of Clinical Sciences, Director of the Unit of
Internal Medicine, University of Milan, Italy
- Anthony Amato, M.D., Vice-Chairman,
Department of Neurology, Brigham and Women’s Hospital, Boston
The live webcast of the event will be accessible from the
“Investors & Media” section of the company's website,
www.acceleronpharma.com.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
therapeutic candidates that regulate cellular growth and repair.
The company is a leader in understanding the biology of the
Transforming Growth Factor-Beta (TGF-beta) protein superfamily, a
large and diverse group of molecules that are key regulators in the
growth and repair of tissues throughout the human body, and in
targeting these pathways to develop important new medicines.
Acceleron has built a highly productive R&D platform that has
generated innovative clinical and preclinical therapeutic
candidates with novel mechanisms of action. These therapeutic
candidates have the potential to significantly improve clinical
outcomes for patients with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151015005509/en/
Acceleron Pharma Inc.Todd James, 617-649-9393Senior Director,
Corporate CommunicationsorMedia:Suda Communications LLCMaureen L.
Suda, 585-387-9248
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024